Thomas B. Ejsing
Research Subjects
Thomas B. Ejsing has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Kristian Linnet
Section of Forensic Chemistry, Department of Forensic Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Frederik V’s vej 11, DK-2100 Copenhagen, Denmark
2 shared publications Anne D. Pedersen
The Centre for Basic Psychiatric Research, Psychiatric Hospital in Aarhus, Denmark
1 shared publication
Latest Publications
- 1 November 2005
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 20 (7) , 493-500
P-glycoprotein interaction with risperidone and 9-OH-risperidone studiedin vitro, in knock-out mice and in drug-drug interaction experiments
The drug transporter P‐glycoprotein (P‐gp) influences drug distribution across the blood‐brain barrier (BBB) by actively extruding drugs into the neural capillaries. Several psychotropic drugs, including nortriptyline (NT) and risperidone (Risp), are substrates of P‐gp. Here we compared the in vitro P‐gp interactions of Risp and its major metabolite, 9‐OH‐Risperidone (OH‐Risp), with their distribution over the BBB in P‐gp knock‐out mice and in rats where P‐gp was inhibited. Km and Vmax were determined by an in vitro ATPase assay, and Vmax/Km ratios of 2.7 and 0.5 were recorded for Risp and OH‐Risp, respectively, suggesting that Risp is a better substrate for P‐gp than OH‐Risp. In Mdr1a (−/−) knock‐out mice, the brain‐serum ratios of both Risp and OH‐Risp were more than ten times those of control mice (14 and 11, respectively). When P‐gp was inhibited with cyclosporine A (CsA) in Wistar rats, the effect was an order of magnitude less than that observed for the knock‐out mice experiments (1–1.5 times the controls), and co‐administration of NT had no effect. In conclusion, both Risp and OH‐Risp interact with P‐gp in vitro, and P‐gp has a profound effect on Risp and OH‐Risp distribution over the BBB, as is evident from the knock‐out mice experiments. Drug–drug interaction effects in relation to P‐gp, however, appear to be more limited. Copyright © 2005 John Wiley & Sons, Ltd.
- 1 November 2005
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 20 (7) , 493-500
P-glycoprotein interaction with risperidone and 9-OH-risperidone studiedin vitro, in knock-out mice and in drug-drug interaction experiments
The drug transporter P‐glycoprotein (P‐gp) influences drug distribution across the blood‐brain barrier (BBB) by actively extruding drugs into the neural capillaries. Several psychotropic drugs, including nortriptyline (NT) and risperidone (Risp), are substrates of P‐gp. Here we compared the in vitro P‐gp interactions of Risp and its major metabolite, 9‐OH‐Risperidone (OH‐Risp), with their distribution over the BBB in P‐gp knock‐out mice and in rats where P‐gp was inhibited. Km and Vmax were determined by an in vitro ATPase assay, and Vmax/Km ratios of 2.7 and 0.5 were recorded for Risp and OH‐Risp, respectively, suggesting that Risp is a better substrate for P‐gp than OH‐Risp. In Mdr1a (−/−) knock‐out mice, the brain‐serum ratios of both Risp and OH‐Risp were more than ten times those of control mice (14 and 11, respectively). When P‐gp was inhibited with cyclosporine A (CsA) in Wistar rats, the effect was an order of magnitude less than that observed for the knock‐out mice experiments (1–1.5 times the controls), and co‐administration of NT had no effect. In conclusion, both Risp and OH‐Risp interact with P‐gp in vitro, and P‐gp has a profound effect on Risp and OH‐Risp distribution over the BBB, as is evident from the knock‐out mice experiments. Drug–drug interaction effects in relation to P‐gp, however, appear to be more limited. Copyright © 2005 John Wiley & Sons, Ltd.
- 1 March 2005
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 20 (2) , 149-153
Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier
The distribution of the antidepressant drug nortriptyline (NT) and its main metabolite E‐10‐hydroxy‐nortriptyline (E‐10‐OH‐NT) across the blood–brain barrier was considered in relation to inhibition of the multidrug transporter P‐glycoprotein (P‐gp). Rats received NT in doses of 25 mg/kg orally, 10 mg/kg i.p. or 25 mg/kg i.p. Half the rats were treated with the P‐glycoprotein inhibitor cyclosporine A (CsA) (200 mg/kg) 2 h prior to NT administration, and the other half served as a control group. NT and the metabolite were extracted from brain and serum by liquid–liquid extraction and analysed by HPLC with UV‐detection. The brain to serum ratio of NT was increased in the CsA treated groups (22.3–26.8) compared with the control groups (16.5–22.7), the difference being statistically significant in two of the three experiments (p<0.05). Increased brain–serum ratios were also found for E‐10‐OH‐NT, but the differences were not statistically significant. These results suggest that inhibition of P‐gp by CsA increases the accumulation of NT in the brain. Administration of the antipsychotic drug risperidone (0.5 mg/kg s.c.), which is a P‐gp substrate, instead of CsA did not exert any measurable influence on the blood–brain ratio of NT concentrations. In conclusion, the results show that drug–drug interaction at P‐gp may influence the intracerebral NT concentration, but apparently, a major inhibition of P‐gp is necessary to attain a measurable effect. Copyright © 2004 John Wiley & Sons, Ltd.
- 1 March 2005
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 20 (2) , 149-153
Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier
The distribution of the antidepressant drug nortriptyline (NT) and its main metabolite E‐10‐hydroxy‐nortriptyline (E‐10‐OH‐NT) across the blood–brain barrier was considered in relation to inhibition of the multidrug transporter P‐glycoprotein (P‐gp). Rats received NT in doses of 25 mg/kg orally, 10 mg/kg i.p. or 25 mg/kg i.p. Half the rats were treated with the P‐glycoprotein inhibitor cyclosporine A (CsA) (200 mg/kg) 2 h prior to NT administration, and the other half served as a control group. NT and the metabolite were extracted from brain and serum by liquid–liquid extraction and analysed by HPLC with UV‐detection. The brain to serum ratio of NT was increased in the CsA treated groups (22.3–26.8) compared with the control groups (16.5–22.7), the difference being statistically significant in two of the three experiments (p<0.05). Increased brain–serum ratios were also found for E‐10‐OH‐NT, but the differences were not statistically significant. These results suggest that inhibition of P‐gp by CsA increases the accumulation of NT in the brain. Administration of the antipsychotic drug risperidone (0.5 mg/kg s.c.), which is a P‐gp substrate, instead of CsA did not exert any measurable influence on the blood–brain ratio of NT concentrations. In conclusion, the results show that drug–drug interaction at P‐gp may influence the intracerebral NT concentration, but apparently, a major inhibition of P‐gp is necessary to attain a measurable effect. Copyright © 2004 John Wiley & Sons, Ltd.